Arca
Skip to content
Tools
Tools

Oxylanthanum carbonate: Complete Response Letter

A complete response letter is FDA's decision not to approve an application as submitted. See NDA 218607's history or Unicycive Therapeutics's company page.

On Jun 29, 2026, FDA declined to approve Oxylanthanum carbonate (NDA 218607) from Unicycive Therapeutics Inc. in its present form, citing facility inspections. openFDA lists it as not yet approved.

  • Letter date: Jun 29, 2026
  • Application: NDA 218607
  • Since then: Not approved

What FDA Cited

FDA's own section headings in the letter; each finds other letters citing it

Facility inspections

The Letter

Text from openFDA

Following a Current Good Manufacturing Practices (CGMP) inspection of me listed in this application, FDA conveyed deficiencies โ€˜o the representative of the facility. The facility should provide satisfactory responses to hese deficiencies to the FDA office indi...โ€ฆ openFDA did not return the full text just now. Open it in the letter search.

Other Letters on This Application

Record

Company
Unicycive Therapeutics Inc.
Application
NDA 218607
Status in openFDA
Unapproved

FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.